Loading...
•
Mar 31, 2023
Glaukos Q1 2023 Earnings Report
Glaukos experienced solid topline growth and advanced its pipeline of novel technologies.
Key Takeaways
Glaukos Corporation reported a 9% year-over-year increase in net sales for Q1 2023, reaching $73.9 million. The company's glaucoma and corneal health segments both saw growth, and the company raised its 2023 net sales guidance to $295 million to $300 million.
Net sales increased by 9% year-over-year to $73.9 million in Q1 2023.
Glaucoma net sales rose by 9% year-over-year to $56.2 million in Q1 2023.
Corneal Health net sales increased by 10% year-over-year to $17.7 million in Q1 2023.
The company raised 2023 net sales guidance to $295 million to $300 million.
Revenue by Segment
Forward Guidance
Glaukos expects 2023 net sales to be in the range of $295 million to $300 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...